Axogen (AXGN)

• Market cap: $707M
• 1 day: 2.11%
• 5 days: 2.84%
• 1 month: -12.12%
• 3 months: -12.07%
• 6 months: 19.83%
• Year to date: -2.74%
• 1 year: 132.17%
• 5 years: 91.02%
• 10 years: 374.70%
• Sector: Healthcare
• Industry: Medical Devices

About: Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Employees: 452

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

14,300% more call options, than puts

Call options by funds: $2.59M | Put options by funds: $18K

100% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 17

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

16% more capital invested

Capital invested by funds: $510M [Q3] → $591M (+$80.9M) [Q4]

10% more funds holding

Funds holding: 157 [Q3] → 172 (+15) [Q4]

1.53% less ownership

Funds ownership: 82.99% [Q3] → 81.46% (-1.53%) [Q4]

32% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 66

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $24 50% upside
• Avg. target: $26 66% upside
• High target: $30 88% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Frank Takkinen 10% 1-year accuracy 2 / 21 met price target	88% upside $30	Buy Initiated	17 Mar 2025
Cantor Fitzgerald Ross Osborn 20% 1-year accuracy 9 / 45 met price target	50% upside $24	Overweight Reiterated	5 Mar 2025
Citizens Capital Markets David Turkaly 15% 1-year accuracy 4 / 26 met price target	63% upside $26	Market Outperform Reiterated	5 Mar 2025
Canaccord Genuity Caitlin Cronin 14% 1-year accuracy 2 / 14 met price target	63% upside $26	Buy Maintained	26 Feb 2025
Citizens Capital Markets Constantine Davides 23% 1-year accuracy 7 / 31 met price target	63% upside $26	Market Outperform Maintained	26 Feb 2025